Evidence map›Paper›PMID 37106787›Full record

ArticleBiology2023

Evaluation of BAFF, APRIL and CD40L in Ocrelizumab-Treated pwMS and Infectious Risk.

Maria Antonella Zingaropoli, Patrizia Pasculli, Matteo Tartaglia, Federica Dominelli, Federica Ciccone, Ambra Taglietti, Valentina Perri, Leonardo Malimpensa, Gina Ferrazzano, Marco Iannetta and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Maria Antonella ZingaropoliDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy.
Patrizia PasculliDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy.ORCID 0000-0002-6678-6865
Matteo TartagliaDepartment of Human Neurosciences, Sapienza University of Rome, 00185 Rome, Italy.
Federica DominelliDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy.ORCID 0000-0002-8059-5088
Federica CicconeDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy.
Ambra TagliettiDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy.
Valentina PerriDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy.
Leonardo MalimpensaDepartment of Human Neurosciences, Sapienza University of Rome, 00185 Rome, Italy.
Gina FerrazzanoDepartment of Human Neurosciences, Sapienza University of Rome, 00185 Rome, Italy.
Marco IannettaInfectious Disease Unit, Department of System Medicine, Tor Vergata University and Hospital, 00133 Rome, Italy.ORCID 0000-0002-6938-8627
Cosmo Del BorgoInfectious Diseases Unit, Santa Maria Goretti Hospital, Sapienza University of Rome, 04110 Latina, Italy.
Miriam LichtnerInfectious Diseases Unit, Santa Maria Goretti Hospital, Sapienza University of Rome, 04110 Latina, Italy.
Claudio Maria MastroianniDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy.ORCID 0000-0002-1286-467X
Antonella ConteDepartment of Human Neurosciences, Sapienza University of Rome, 00185 Rome, Italy.ORCID 0000-0002-6338-2961
Maria Rosa CiardiDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy.
Sapienza University of Rome · ITOspedale Santa Maria Goretti · ITIstituto Neurologico Mediterraneo · ITUniversity of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe anti-CD20 monoclonal antibody ocrelizumab has been widely employed in the treatment of people with multiple sclerosis (pwMS). However, its B-cell-depleting effect may induce a higher risk of infectious events and alterations in the secretion of B-cell-activating factors, such as BAFF, APRIL and CD40L.

methodsThe aim of this study was to investigate plasma BAFF, APRIL and CD40L levels and their relationship with infectious risk in ocrelizumab-treated pwMS at baseline (T0), at 6 months (T6) and at 12 months (T12) after starting the treatment. As a control group, healthy donors (HD) were enrolled too.

resultsA total of 38 pwMS and 26 HD were enrolled. At baseline, pwMS showed higher plasma BAFF (

Indexed as

anti-CD20APRILBAFFCD40LDMTsinfectious riskocrelizumabpwMS

Identifiers

PMID37106787
PMCPMC10135639
OpenAlexW4365146104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.